December 5, 2023 12:00 am EDT

JERSEY CITY, N.J., DECEMBER 5, 2023 – Organon (NYSE: OGN) today announced that Dr. Sandra Milligan, global Head of
Research and Development, will be leaving the company on January 5, 2024. Effective January 1, 2024, Dr. Juan Camilo
Arjona Ferreira will assume the role of Head of Research and Development in addition to his current responsibilities
as the company’s Chief Medical Officer.

“I am grateful to Sandy for her contributions to the executive leadership team as we shaped Organon’s
commitment to women’s health. She helped to establish this company, built a strong team and fostered a strong
culture,” said Kevin Ali, Organon’s CEO. “Sandy has also been an incredible ambassador for Organon
as we’ve established our reputation as a women’s health company.”

Since 2021, Dr. Milligan has led Organon’s efforts to expand its women’s health focus from contraception
and fertility to include products and research in areas such as post-partum hemorrhage, bacterial vaginosis,
polycystic ovary syndrome and endometriosis. Dr. Milligan led the effort to develop Organon’s R&D
capabilities to support its current portfolio and build a pipeline to drive future growth.

“As we continue to advance our current portfolio and deliver on the promise of the innovations within our
pipeline, Dr. Arjona Ferreira brings a strong track record of developing treatments in women’s health, along
with the leadership and collaborative spirit to help us in achieving our goals,” added Ali.

Dr. Arjona Ferreira has over two decades of clinical research and development experience and a strong background in
women’s health. Prior to joining Organon in July 2023, he was CMO of Myovant Sciences Inc. He also previously
held leadership roles in women’s health and other therapeutic areas at Shionogi & Co., Ltd. and Merck and
Co. Earlier in his career, Dr. Arjona Ferreira practiced as an OB-GYN in university hospitals and private practice.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives.
Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars
business and a large franchise of established medicines across a range of therapeutic areas. Organon’s
existing products produce strong cash flows that support investments in innovation and future growth opportunities
in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with
biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast
growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and
approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com
and connect with us on LinkedIn,
Instagram,
X (formally known as Twitter) and Facebook.